Integrating Type 2 symptoms into SLE management strategies

Urowitz provided an overview of the key differences between the two types of lupus, highlighting the key symptoms of Type 2 lupus and their similarity to other conditions, such as COVID-19. He emphasized the importance of including these symptoms as outcome measures in clinical trials, and addressed patient–physician discordance and the need for a multidisciplinary approach involving social workers, nurses, psychologists, and psychiatrists. Although the pathogenesis of Type 2 lupus remains unclear, the steering committee members questioned the inflammatory contribution and the necessity of further investigation into its underlying mechanisms.